請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69093
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 徐莞曾(Wan-Tseng Hsu) | |
dc.contributor.author | Tsun-Yu Yang | en |
dc.contributor.author | 楊淳聿 | zh_TW |
dc.date.accessioned | 2021-06-17T02:51:34Z | - |
dc.date.available | 2025-08-17 | |
dc.date.copyright | 2020-09-02 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-08-17 | |
dc.identifier.citation | 1. Shimizu, T., Lengalova, A., Martínek, V., et al., Heme: emergent roles of heme in signal transduction, functional regulation and as catalytic centres. Chemical Society Reviews, 2019. 48: p. 5624. 2. Abbaspour, N., Hurrell, R., and Kelishadi, R., Review on iron and its importance for human health. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2014. 19: p. 164. 3. Musallam, K.M. and Taher, A.T., Iron deficiency beyond erythropoiesis: should we be concerned? Current Medical Research and Opinion, 2018. 34: p. 81. 4. Anand, I.S. and Gupta, P., Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation, 2018. 138: p. 80. 5. Zhang, H., Zhabyeyev, P., Wang, S., et al., Role of iron metabolism in heart failure: From iron deficiency to iron overload. Biochim Biophys Acta Mol Basis Dis, 2019. 1865: p. 1925. 6. von Haehling, S., Ebner, N., Evertz, R., et al., Iron Deficiency in Heart Failure: An Overview. JACC: Heart Failure, 2019. 7: p. 36. 7. Waldvogel-Abramowski, S., Waeber, G., Gassner, C., et al., Physiology of iron metabolism. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2014. 41: p. 213. 8. World Health Organization. Worldwide prevalence of anaemia 1993-2005: WHO global database on anaemia. 2008. https://apps.who.int/iris/bitstream/handle/10665/43894/9789241596657_eng.pdf. Accessed August 17, 2020. 9. Sîrbu, O., Floria, M., Dascalita, P., et al., Anemia in heart failure - from guidelines to controversies and challenges. Anatolian journal of cardiology, 2018. 20: p. 52. 10. Muñoz, M., Gómez-Ramírez, S., Besser, M., et al., Current misconceptions in diagnosis and management of iron deficiency. Blood transfusion = Trasfusione del sangue, 2017. 15: p. 422. 11. Cappellini, M.D., Comin-Colet, J., de Francisco, A., et al., Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. American journal of hematology, 2017. 92: p. 1068. 12. Weiss, G. and Goodnough, L.T., Anemia of Chronic Disease. New England Journal of Medicine, 2005. 352: p. 1011. 13. Percy, L., Mansour, D., and Fraser, I., Iron deficiency and iron deficiency anaemia in women. Best Practice Research Clinical Obstetrics Gynaecology, 2017. 40: p. 55. 14. Ponikowski, P., Voors, A.A., Anker, S.D., et al., 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2016. 37: p. 2129. 15. Klip, I.T., Comin-Colet, J., Voors, A.A., et al., Iron deficiency in chronic heart failure: An international pooled analysis. American Heart Journal, 2013. 165: p. 575. 16. Wienbergen, H., Pfister, O., Hochadel, M., et al., Usefulness of Iron Deficiency Correction in Management of Patients With Heart Failure [from the Registry Analysis of Iron Deficiency-Heart Failure (RAID-HF) Registry]. Am J Cardiol, 2016. 118: p. 1875. 17. Wienbergen, H., Pfister, O., Hochadel, M., et al., Long-term effects of iron deficiency in patients with heart failure with or without anemia: the RAID-HF follow-up study. Clinical Research in Cardiology, 2019. 108: p. 93. 18. McDonagh, T., Damy, T., Doehner, W., et al., Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. European journal of heart failure, 2018. 20: p. 1664. 19. Kang, C.-K., Pope, M., Lang, C.C., et al., Iron deficiency in heart failure: Efficacy and safety of intravenous iron therapy. Cardiovascular Therapeutics, 2017. 35: p. e12301. 20. Haase, V.H., Hypoxic regulation of erythropoiesis and iron metabolism. American journal of physiology. Renal physiology, 2010. 299: p. F1. 21. Jelkmann, W., Molecular Biology of Erythropoietin. Internal Medicine, 2004. 43: p. 649. 22. Koury, M.J., Erythropoietin: the story of hypoxia and a finely regulated hematopoietic hormone. Experimental Hematology, 2005. 33: p. 1263. 23. Farsijani, N.M., Liu, Q., Kobayashi, H., et al., Renal epithelium regulates erythropoiesis via HIF-dependent suppression of erythropoietin. The Journal of clinical investigation, 2016. 126: p. 1425. 24. Dec, G.W., Anemia and Iron Deficiency — New Therapeutic Targets in Heart Failure? New England Journal of Medicine, 2009. 361: p. 2475. 25. Weiss, G., Ganz, T., and Goodnough, L.T., Anemia of inflammation. Blood, 2019. 133: p. 40. 26. Khalil, S., Delehanty, L., Grado, S., et al., Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. The Journal of experimental medicine, 2018. 215: p. 661. 27. Forrester, S.J., Booz, G.W., Sigmund, C.D., et al., Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology. Physiological reviews, 2018. 98: p. 1627. 28. Arendse, L.B., Danser, A.H.J., Poglitsch, M., et al., Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. Pharmacological reviews, 2019. 71: p. 539. 29. Vlahakos, D.V., Tsioufis, C., Manolis, A., et al., Inhibition of the renin-angiotensin system in the cardiorenal syndrome with anaemia: a double-edged sword. J Hypertens, 2019. 37: p. 2145. 30. Arora, N.P. and Ghali, J.K., Anemia and iron deficiency in heart failure. Heart Fail Clin, 2014. 10: p. 281. 31. Shah, R. and Agarwal, A.K., Anemia associated with chronic heart failure: current concepts. Clinical interventions in aging, 2013. 8: p. 111. 32. Anand, I.S., Anemia and Chronic Heart Failure: Implications and Treatment Options. Journal of the American College of Cardiology, 2008. 52: p. 501. 33. Leshem-Rubinow, E., Steinvil, A., Zeltser, D., et al., Association of angiotensin-converting enzyme inhibitor therapy initiation with a reduction in hemoglobin levels in patients without renal failure. Mayo Clinic proceedings, 2012. 87: p. 1189. 34. Cheungpasitporn, W., Thongprayoon, C., Chiasakul, T., et al., Renin-angiotensin system inhibitors linked to anemia: a systematic review and meta-analysis. QJM: An International Journal of Medicine, 2015. 108: p. 879. 35. Tymińska, A., Kapłon-Cieślicka, A., Ozierański, K., et al., Anemia at Hospital Admission and Its Relation to Outcomes in Patients With Heart Failure (from the Polish Cohort of 2 European Society of Cardiology Heart Failure Registries). The American Journal of Cardiology, 2017. 119: p. 2021. 36. Ambrosy, A.P., Gurwitz, J.H., Tabada, G.H., et al., Incident anaemia in older adults with heart failure: rate, aetiology, and association with outcomes. Eur Heart J Qual Care Clin Outcomes, 2019. 5: p. 361. 37. Ronco, C., Bellasi, A., and Di Lullo, L., Cardiorenal Syndrome: An Overview. Adv Chronic Kidney Dis, 2018. 25: p. 382. 38. Zannad, F. and Rossignol, P., Cardiorenal Syndrome Revisited. Circulation, 2018. 138: p. 929. 39. Kumar, U., Wettersten, N., and Garimella, P.S., Cardiorenal Syndrome: Pathophysiology. Cardiology clinics, 2019. 37: p. 251. 40. Donati, A., Carsetti, A., and Damiani, E., The role of cardiac dysfunction in multiorgan dysfunction. Current Opinion in Anesthesiology, 2016. 29: p. 172. 41. Tyagi, A. and Aeddula, N.R. Azotemia [Updated 2020 Feb 21]. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. https://www.ncbi.nlm.nih.gov/books/NBK538145/. Accessed August 20, 2020. 42. Jhund, P.S. and McMurray, J.J.V., The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart, 2016. 102: p. 1342. 43. Bayard, G., Da Costa, A., Pierrard, R., et al., Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation. International journal of cardiology. Heart vasculature, 2019. 25: p. 100418. 44. Sauer, A.J., Cole, R., Jensen, B.C., et al., Practical guidance on the use of sacubitril/valsartan for heart failure. Heart failure reviews, 2019. 24: p. 167. 45. Ralli, S., Horwich, T.B., and Fonarow, G.C., Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. American Heart Journal, 2005. 150: p. 1220. 46. Tirmenstajn-Jankovic, B., Dimkovic, N., Perunicic-Pekovic, G., et al., Anemia is independently associated with NT-proBNP levels in asymptomatic predialysis patients with chronic kidney disease. Hippokratia, 2013. 17: p. 307. 47. Karakoyun, I., Colak, A., Arslan, F.D., et al., Anemia considerations when assessing natriuretic peptide levels in ED patients. Am J Emerg Med, 2017. 35: p. 1677. 48. Damman, K., Gori, M., Claggett, B., et al., Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC Heart Fail, 2018. 6: p. 489. 49. Tersalvi, G., Dauw, J., Martens, P., et al., Impact of Sacubitril-Valsartan on Markers of Glomerular Function. Curr Heart Fail Rep, 2020. 17: p. 145. 50. Cohen-Solal, A., Jacobson, A.F., and Piña, I.L., Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance. ESC heart failure, 2017. 4: p. 499. 51. Felker, G.M., Ellison, D.H., Mullens, W., et al., Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 2020. 75: p. 1178. 52. Yancy, C.W., Jessup, M., Bozkurt, B., et al., 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 2013. 62: p. e147. 53. Mistry, R., Hosoya, H., Kohut, A., et al., Iron deficiency in heart failure, an underdiagnosed and undertreated condition during hospitalization. Annals of Hematology, 2019. 98: p. 2293. 54. Bliss, S., Anemia and Oxygen Delivery. Veterinary Clinics of North America: Small Animal Practice, 2015. 45: p. 917. 55. Shimomura, A., Nagata, N., Shimbo, T., et al., New predictive model for acute gastrointestinal bleeding in patients taking oral anticoagulants: A cohort study. J Gastroenterol Hepatol, 2018. 33: p. 164. 56. Brown, L.A.E. and Boos, C.J., Atrial fibrillation and heart failure: Factors influencing the choice of oral anticoagulant. International Journal of Cardiology, 2017. 227: p. 863. 57. Reed, B.N., Rodgers, J.E., and Sueta, C.A., Polypharmacy in heart failure: drugs to use and avoid. Heart Fail Clin, 2014. 10: p. 577. 58. Kumar, N.L., Claggett, B.L., Cohen, A.J., et al., Association between an increase in blood urea nitrogen at 24 hours and worse outcomes in acute nonvariceal upper GI bleeding. Gastrointestinal Endoscopy, 2017. 86: p. 1022. 59. Solomon, S.D., Claggett, B., Desai, A.S., et al., Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ Heart Fail, 2016. 9: p. e002744. 60. Mullens, W., Damman, K., Harjola, V.-P., et al., The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019. 21: p. 137. 61. Islam, M.S., The Art and Science of Using Diuretics in the Treatment of Heart Failure in Diverse Clinical Settings. Adv Exp Med Biol, 2018. 1067: p. 47. 62. Okumura, N., Jhund Pardeep, S., Gong, J., et al., Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. Circulation: Heart Failure, 2016. 9: p. e003212. 63. Agrawal, S., Agrawal, N., Garg, J., et al., Heart failure and chronic kidney disease: should we use spironolactone? Am J Med Sci, 2015. 350: p. 147. 64. Pitt, B., Zannad, F., Remme, W.J., et al., The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine, 1999. 341: p. 709. 65. Buckley, L.F., Carter, D.M., Matta, L., et al., Intravenous Diuretic Therapy for the Management of Heart Failure and Volume Overload in a Multidisciplinary Outpatient Unit. JACC: Heart Failure, 2016. 4: p. 1. 66. Kiernan, M.S., Stevens, S.R., Tang, W.H.W., et al., Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials. Journal of cardiac failure, 2018. 24: p. 428. 67. Nappi, J.M., A retrospective evaluation of the efficacy of intravenous bumetanide and comparison of potency with furosemide. Pharmacy practice, 2013. 11: p. 44. 68. Cox, Z.L., Hung, R., Lenihan, D.J., et al., Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial. JACC: Heart Failure, 2020. 8: p. 157. 69. Felker, G.M., Lee, K.L., Bull, D.A., et al., Diuretic strategies in patients with acute decompensated heart failure. The New England journal of medicine, 2011. 364: p. 797. 70. DeVore, A.D., Hasselblad, V., Mentz, R.J., et al., Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF. European Journal of Heart Failure, 2015. 17: p. 340. 71. Shulenberger, C.E., Jiang, A., Devabhakthuni, S., et al., Efficacy and Safety of Intravenous Chlorothiazide versus Oral Metolazone in Patients with Acute Decompensated Heart Failure and Loop Diuretic Resistance. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2016. 36: p. 852. 72. Vardeny, O., Claggett, B., Kachadourian, J., et al., Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. European journal of heart failure, 2019. 21: p. 337. 73. Pharithi, R.B., Ferre-Vallverdu, M., Maisel, A.S., et al., Sacubitril-Valsartan in a routine community population: attention to volume status critical to achieving target dose. ESC Heart Failure, 2020. 7: p. 159. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69093 | - |
dc.description.abstract | 研究背景 貧血為心衰竭的共病症之一,會降低心衰竭病人之灌流液 (perfusate) 品質、運動耐受性 (exercise capacity) 並增加住院率或死亡率。貧血主因之一為鐵質缺乏,因此國際心衰竭治療指引建議每年必須追蹤一次鐵質概況 (iron profile),並根據血紅素測量值給予鐵劑治療。此外,慢性腎臟疾病或使用腎素-血管收縮素-醛固酮系統 (renin-angiotensin-aldosterone system, RAAS) 阻斷劑等亦為貧血可能原因,而目前最新 RAAS 阻斷藥物 sacubitril/valsartan 療效是否與病人的貧血狀況相互影響尚無佐證。本研究先探討臺大醫院心衰竭病人貧血的追蹤狀況,再初步分析貧血與sacubitril/valsartan 治療對心衰竭病人預後之影響。 研究方法與結果 首先,本研究回溯性分析 2017 年 1 月 1 日至 2019 年 12 月 31 日之臺大醫院心衰竭病人檢驗數據,於699 位心衰竭病人中,貧血盛行率為 54.1%,每年規律追蹤血紅素和鐵質概況的比率分別為 61.8% 和 7.2%。接著,回溯 2020 年 4 月 1 日前啟用 sacubitril/valsartan 的心衰竭病人之檢驗數據、共病症與併用藥,以死亡或心臟移植事件進行單變項分析和存活分析。於 236 位接受 sacubitril/valsartan 治療之心衰竭病人中,貧血盛行率 51.3%。與死亡或心臟移植事件顯著相關之變項包含病人用藥前之 NT-proBNP (存活 4804 ± 6899 pg/mL vs. 事件 6395 ± 7289 pg/mL,p = 0.0454) 、左心室射出分率 (left ventricular ejection fraction, LVEF) (存活 30.60 ± 7.15% vs. 事件 25.72 ± 7.20%,p = 0.0020) 及血液尿素氮 (blood urea nitrogen, BUN) (存活 25.6 ± 14.2 mg/dL vs. 事件 32.5 ± 21.8 mg/dL,p = 0.0489)。此外,用藥後 12 個月血紅素低於12 g/dL 者,死亡或心臟移植事件發生率顯著增加 (風險比值 3.714,95% 信賴區間 = 1.205 – 11.44,p = 0.0037)。 結論 本研究顯示臺大醫院心衰竭病人的貧血和鐵質追蹤狀況尚不符合國際治療指引建議,而影響 sacubitril/valsartan 治療成效的變項包含 NT-proBNP、LVEF、BUN 和血紅素。未來建議延長觀察期限並擴大病人數目,利用多變項迴歸分析,釐清貧血影響 sacubitril/valsartan 治療成效之關係。 | zh_TW |
dc.description.abstract | Background Anemia, one of the common comorbidities of heart failure, will decrease perfusate quality and exercise capacity as well as increase hospitalization and mortality. Iron deficiency is one of its major causes. Therefore, international guidelines have recommended that iron profiles be evaluated annually. Iron deficiency should be treated with intravenous iron, with the dose calculated according to the hemoglobin levels. Furthermore, using renin-angiotensin-aldosterone system (RAAS) blockers can also cause anemia. The mutual effects of the newest RAAS blocker, sacubitril/valsartan, and anemia on heart failure patients are currently unknown. The aim of this study is to audit whether iron profiles are adequately evaluated at NTUH, as well as investigate the effects of anemia and sacubitril/valsartan therapy on heart failure patients. Methods and Results First, we retrospectively analyzed the laboratory data of heart failure patients at NTUH from January 1, 2017 to December 31 2019. Prevalence of anemia was 54.1% in 699 patients. Regular hemoglobin and iron profile evaluations accounted for 61.8% and 7.2%, respectively. Next, we retrospectively analyzed the laboratory data, comorbidities and concurrent medications of patients who initiated sacubitril/valsartan before April 1, 2020. Univariate analysis and survival analysis were performed with death or heart transplant as the composite outcome. Anemia prevalence was 51.3% in 236 patients. Factors associated with patient outcome included baseline NT-proBNP (survivors 4804 ± 6899 pg/mL vs. event 6395 ± 7289 pg/mL, p = 0.0454), LVEF (survivors 30.60 ± 7.15% vs. event 25.72 ± 7.20%, p = 0.0020), and BUN (survivors 25.6 ± 14.2 mg/dL vs. event 32.5 ± 21.8 mg/dL, p = 0.0489). Hemoglobin level below 12 mg/dL at 12 months after therapy initiation also significantly increased risk of death or heart transplant (hazard ratio 3.714, 95% confidence interval 1.205 – 11.44, p = 0.0037) Conclusion This study showed that anemia and iron deficiency follow-ups were not adequately performed at NTUH. Factors affecting sacubitril/valsartan therapy outcomes included NT-proBNP, LVEF, BUN and hemoglobin levels. Future studies are recommended to increase patient numbers and lengthen observation period. The effect of anemia on sacubitril/valsartan therapy should be assessed with multivariate regression analysis. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T02:51:34Z (GMT). No. of bitstreams: 1 U0001-1608202023210000.pdf: 3836499 bytes, checksum: 0d954f03430cec0e7eeeb480c4e7aa6c (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 口試委員會審定書 i 誌謝 ii 目錄 iii 圖目錄 v 表目錄 vi 中文摘要 vii Abstract viii 第一章 緒論 1 壹、 鐵質缺乏 1 貳、 慢性病所致之貧血 4 參、 灌流簡介 7 肆、 Sacubitril/valsartan 簡介 8 伍、 研究目的 9 第二章 研究方法 10 壹、 貧血與鐵質缺乏的篩檢、治療與追蹤現況 10 一、 收集心衰竭病人貧血與鐵質缺乏之檢驗數據 10 二、 統計分析 11 貳、 貧血與 sacubitril/valsartan 治療對心衰竭病人預後之影響 11 一、 收集心衰竭病人之疾病狀態、用藥紀錄與檢驗數據 11 二、 數據整理 13 三、 資料缺失之定義暨處理方式 14 四、 統計分析 14 第三章 結果 16 壹、 貧血與鐵質缺乏的篩檢、治療與追蹤現況 16 一、 心衰竭病人貧血與鐵質缺乏之發生率與盛行率 16 二、 心衰竭病人之血紅素與鐵質概況追蹤狀況 16 三、 心衰竭病人之紅血球形態 16 四、 鐵質缺乏病人之鐵劑治療狀況 17 貳、 貧血與 sacubitril/valsartan 治療對心衰竭病人預後之影響 17 一、 Sacubitril/valsartan 各劑量之使用人數 17 二、 評估腎臟灌流之檢驗數據 17 三、 與腎臟灌流相關之其他變項 18 四、 與貧血相關的變項 18 五、 與灌流之動力學相關的變項 19 六、 檢驗數據之監測狀況 20 第四章 討論 21 壹、 貧血與鐵質缺乏的篩檢、治療與追蹤現況 21 一、 心衰竭病人鐵質缺乏之盛行率與追蹤狀況 21 二、 心衰竭病人貧血之盛行率與追蹤狀況 21 貳、 貧血與 sacubitril/valsartan 治療對心衰竭病人預後之影響 22 一、 器官灌流與心衰竭病人預後預後之關係 22 二、 貧血對心衰竭病人預後之影響 22 三、 心輸出量對心衰竭病人預後之影響 24 四、 利尿劑與體容積平衡對心衰竭病人預後之影響 25 五、 併用礦皮質素受體阻斷劑 (MRA) 對於心衰竭病人預後之影響 26 六、 研究限制:利尿劑同等劑量計算方式的依據 27 第五章 結論與展望 29 第六章 參考文獻 30 第七章 圖表 37 | |
dc.language.iso | zh-TW | |
dc.title | 初探貧血與 sacubitril/valsartan 治療對心衰竭病人預後之影響 | zh_TW |
dc.title | A Pilot Study Investigating the Effects of Anemia and Sacubitril/Valsartan Therapy on the Outcome of Heart Failure with Reduced Ejection Fraction Patients | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李啟明(Chii-Ming Lee),林芳如(Fang-Ju Lin) | |
dc.subject.keyword | 心衰竭,貧血,鐵質缺乏,灌流,RAAS 阻斷劑, | zh_TW |
dc.subject.keyword | Heart failure,Anemia,Iron deficiency,Perfusion,RAAS blocker, | en |
dc.relation.page | 56 | |
dc.identifier.doi | 10.6342/NTU202003634 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-08-18 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1608202023210000.pdf 目前未授權公開取用 | 3.75 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。